Want to see ORKA full AI Analyst Report?
Top Page
Oruka Therapeutics
(NASDAQ:ORKA)
Select Model
Select Model
Rating:60Neutral
Price Target:
$113.00
▲(13.64% Upside)
Action:Reiterated
Date:08/25/26
ORKA scores as moderate overall, driven primarily by a strong, low-debt balance sheet but offset by a pre-revenue profile with widening losses and increasing cash burn. Technicals are a supportive secondary factor with strong price trend and positive momentum. Valuation remains a headwind due to negative earnings (negative P/E) and no dividend support, while corporate events are mildly positive but not decisive.
Positive Factors
Low Leverage
Extremely low leverage gives Oruka substantial financial flexibility while it funds clinical development. The large equity base and sharply higher assets provide a stronger capital foundation than many early-stage biotech peers, although ongoing losses remain a constraint.
Negative Factors
Pre-Revenue Model
Oruka has no product revenue to offset research and development spending, leaving its fundamental outlook dependent on clinical progress, licensing, partnerships or future commercialization. Without successful programs, the company lacks an internally generated funding base.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Extremely low leverage gives Oruka substantial financial flexibility while it funds clinical development. The large equity base and sharply higher assets provide a stronger capital foundation than many early-stage biotech peers, although ongoing losses remain a constraint.
Read all positive factors
Oruka Therapeutics (ORKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.74B
Dividend YieldN/A
Average Volume (3M)1.51M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth32.27%
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.47
Shares Outstanding66,209,700
10 Day Avg. Volume970,993
30 Day Avg. Volume1,505,454
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$156.40Price Target Upside57.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.32
Revenue Forecast (FY)N/A
Oruka Therapeutics Business Overview & Revenue Model
Company Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 tha...
How the Company Makes Money
As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available information indicating it generates recurring revenue from product sales. null...
Oruka Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
82
Very Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -114.00K | -83.00K | -27.00K | -114.00K | -91.00K | -93.00K |
| EBITDA | -141.65M | -105.35M | -82.23M | -9.81M | -19.23M | -9.64M |
| Net Income | -132.89M | -105.43M | -83.72M | -9.93M | -19.32M | -9.74M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 488.62M | 396.02M | 43.09M | 54.92M | 50.43M |
| Cash, Cash Equivalents and Short-Term Investments | 873.56M | 337.04M | 375.65M | 42.45M | 53.36M | 49.07M |
| Total Debt | 2.55M | 1.93M | 968.00K | 383.00K | 483.00K | 450.00K |
| Total Liabilities | 24.84M | 16.69M | 13.80M | 1.41M | 3.88M | 3.91M |
| Stockholders Equity | 1.11B | 471.93M | 382.22M | 41.67M | 51.04M | 46.52M |
Cash Flow | ||||||
| Free Cash Flow | -101.15M | -88.42M | -58.03M | -10.91M | -18.80M | -7.74M |
| Operating Cash Flow | -100.92M | -88.21M | -57.84M | -10.91M | -18.76M | -7.72M |
| Investing Cash Flow | -569.86M | -96.75M | -330.13M | -2.00K | -43.00K | -19.00K |
| Financing Cash Flow | 873.85M | 170.31M | 449.54M | 0.00 | 23.09M | 48.45M |
Oruka Therapeutics Technical Analysis
Neutral
99.44
Price Trends
93.94
Positive
79.09
Positive
56.27
Positive
Market Momentum
2.71
Positive
44.92
Neutral
6.32
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Neutral. The current price of 99.44 is below the 20-day moving average (MA) of 103.44, above the 50-day MA of 93.94, and above the 200-day MA of 56.27, indicating a neutral trend. The MACD of 2.71 indicates Positive momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 6.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORKA.
Oruka Therapeutics Risk Analysis
Oruka Therapeutics disclosed 1 risk factors in its most recent earnings report. Oruka Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oruka Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $6.74B | -40.26 | -20.76% | ― | ― | 32.27% | |
58 Neutral | $1.73B | -66.67 | 442.91% | ― | 107.73% | 82.33% | |
56 Neutral | $641.19M | -3.00 | -467.49% | ― | 3995.74% | 24.87% | |
56 Neutral | $1.63B | -7.98 | -41.49% | ― | ― | -63.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $455.62M | -5.86 | -38.71% | ― | ― | 10.44% | |
45 Neutral | $954.60M | -5.12 | -48.22% | ― | ― | -10.16% |
* Healthcare Sector Average
ORKA
Oruka Therapeutics
99.44
84.17
551.21%
VSTM
Verastem
7.39
-1.84
-19.93%
ANAB
AnaptysBio
58.00
44.58
332.26%
CMPX
Compass Therapeutics
2.43
-1.06
-30.37%
OLMA
Olema Pharmaceuticals
10.85
5.33
96.56%
BCAX
Bicara Therapeutics Inc.
24.73
12.82
107.64%
Oruka Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer
Positive
Aug 24, 2026
On July 22, 2026, Oruka Therapeutics appointed veteran commercial executive Todd Edwards as Chief Commercial Officer, with his employment commencing on August 24, 2026. Edwards brings extensive commercialization experience from senior roles at Arc...
Executive/Board ChangesShareholder Meetings
Oruka Therapeutics Shareholders Back Governance and Executive Pay
Positive
Jun 4, 2026
At its June 2, 2026 annual meeting, Oruka Therapeutics stockholders elected two Class II directors, Lawrence Klein and Chris Martin, to serve on the board until the 2029 annual meeting, reinforcing continuity in the company’s governance stru...
Business Operations and StrategyRegulatory Filings and Compliance
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
Neutral
Jun 1, 2026
On May 29, 2026, Oruka Therapeutics, Inc. amended its IL-23 License Agreement with Paragon Therapeutics, Inc. to expand the licensed field for its IL-23 program, including ORKA-001, to cover all therapeutic, prophylactic, palliative and diagnostic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.